Medscape2d
New COPD Treatments Shift Focus From Symptoms to Survival
With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...
Healio10d
Adherence to asthma biologics varies by therapy given, tends to be low
Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...
News 99d
Oklahoma Allergy and Asthma Clinic pushing back against insurance changes
The Oklahoma Allergy and Asthma clinic is pushing back against proposed changes in coverage for asthma medications covered by ...
Pharmabiz10d
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
BCBSOK could impact asthma patients needing injections
Oklahomans with severe asthma who are insured with BlueCross and BlueShield of Oklahoma (BCBSOK), may have to give themselves ...
News on 69d
Oklahoma Allergy and Asthma Clinic pushing back against insurance changes
The changes will go into effect April 15, 2025. Four medications will be impacted by the changes: Fasenra (benralizumab), used to treat adults with eosinophilic asthma. Tezspire (tezepelumab ...
Drug Eruptions Market on Track for Steady and Promising Growth by 2032, Reports DelveInsight
• According to DelveInsight, the market for Drug Eruptions in the 7MM is projected to grow significantly during the study ...
pharmaphorum1d
FDA says no to AZ's Fasenra for nasal polyp indication
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...